Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases (BMs). The phase 3b/4 DESTINY-Breast12 study investigated T-DXd in patients with HER2+ mBC and is, to our knowledge, the largest prospective study of T-DXd in patients with BMs in this setting. Patients (stable/active BMs (n = 263) and no BMs (n = 241)) treated with one or more prior anti-HER2–based regimens received T-DXd (5.4 mg per kg). Primary endpoints were progression-free survival (PFS; BMs cohort) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (non-BMs cohort). Additional endpoints included central nervous system (CNS) PFS, ORR, time to second progression, CNS ORR (BMs cohort), incidence of new symptomatic CNS metastases (non-BMs cohort), time to progression, duration of response, overall survival and safety (both cohorts). No formal hypothesis testing was conducted for this single-arm, open-label study. In the BMs cohort, 12-month PFS was 61.6% (95% confidence interval (CI): 54.9–67.6), and 12-month CNS PFS was 58.9% (95% CI: 51.9–65.3). In the non-BMs cohort, ORR was 62.7% (95% CI: 56.5–68.8). Grade 3 or higher adverse events occurred in 51% (BMs cohort) and 49% (non-BMs cohort) of patients. Investigator-reported interstitial lung disease/pneumonitis occurred in 16% (grade ≥3: 3%) of patients with BMs and 13% (grade ≥3: 1%) of patients without BMs. These data show substantial and durable overall and intracranial activity for T-DXd, supporting its use in previously treated patients with HER2+ mBC irrespective of stable/active baseline BMs. ClinicalTrials.gov identifier: NCT04739761.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Self-citationLin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
Self-citation
Metadata
- Authors
- Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., Baron-Hay, S., Gión, M., Guarneri, V., Bianchini, G., Wildiers, H., Escrivá-de-Romaní, S., Prahladan, M., Bridge, H., Kuptsova-Clarkson, N., Scotto, N., Verma, S., Lin, N. U., the DESTINY-Breast12 study group, Yeo, B., McCarthy, N., McCartney, A., Clay, T., Murray, N., Gombos, A., Collignon, J., De Cuypere, E., Jerzak, K., Chia, S., Maraldo, M., Rønlev, J., Brix, E., Tanner, M., Mattson, J., Huovinen, R., Wimberger, P., Reinisch, M., Tesch, H., Untch, M., Fasching, P., Park-Simon, T.-W., Tio, J., Braun, M., Grischke, E. M., Marmé, F., van Mackelenbergh, M., McCaffrey, J., De Laurentiis, M., Caruso, M., Berardi, R., Biganzoli, L., Fotia, V., Yamashita, T., Tsurutani, J., Tsugawa, K., Tomioka, N., de Boer, M., Houtsma, D., Pilskog, M., Engebråten, O., Sætersdal, A., Wysocki, P., Nowecki, Z., Radecka, B., Jassem, J., Duchnowska, R., Simões, J., Cardoso, F., Sousa, A. R., Losada, M. J. V., Manich, C. S., Gregori, J. G., Marti, M. P. L., Borrego, M. R., Castán, J. C., López, R. L., Sanchez, C. R., Flores, E. G., González, C. H., del Prado, P. M., Schiza, A., Killander, F., Klint, L., Rossi, L., Aebi, S., Zaman, K., Hall, P., & Anders, C.
- Venue
- Nature Medicine
- Published
- 2024-09-13
- Volume
- 30
- Issue
- 12
- Pages
- 3717-3727
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4402514945
- Cited by
- 227
- References
- 3
- FWCI
- 34.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. https://app.cochat.ai/papers/10.1038/s41591-024-03261-7
- The paper
- Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Higgins, M. J., Connolly, R. M., Baron-Hay, S., Gión, M., Guarneri, V., Bianchini, G., Wildiers, H., Escrivá-de-Romaní, S., Prahladan, M., Bridge, H., Kuptsova-Clarkson, N., . . . Anders, C. (2024). Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03261-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.